Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Radford

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2013
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trialFranck Morschhauser, John Radford, Achiel Van Hoof, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 28, 2010
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphomaSally F Barrington, Wendi Qian, Edward J Somer, et al.
Leukemia & Lymphoma|February 25, 2015
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphomaNina D Wagner-Johnston, Andrè Goy, Maria A Rodriguez, et al.
The New England Journal of Medicine|April 23, 2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphomaJohn Radford, Tim Illidge, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID StudySally F Barrington, Elizabeth H Phillips, Nicholas Counsell, et al.
Annals of Hematology|November 29, 2019
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialAndrea Kühnl, Clare Peckitt, Bijal Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2019
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaBrad S Kahl, Mehdi Hamadani, John Radford, et al.
Blood|April 9, 2008
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialAnton Hagenbeek, Ole Gadeberg, Peter Johnson, et al.
The Oncologist|February 26, 2014
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study)Marta Bruno Ventre, Andrés J M Ferreri, Mary Gospodarowicz, et al.
Blood|September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphomaPhilippe Armand, Ann Janssens, Giuseppe Gritti, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2013
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trialFranck Morschhauser, John Radford, Achiel Van Hoof, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 28, 2010
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphomaSally F Barrington, Wendi Qian, Edward J Somer, et al.
Leukemia & Lymphoma|February 25, 2015
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphomaNina D Wagner-Johnston, Andrè Goy, Maria A Rodriguez, et al.
The New England Journal of Medicine|April 23, 2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphomaJohn Radford, Tim Illidge, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID StudySally F Barrington, Elizabeth H Phillips, Nicholas Counsell, et al.
Annals of Hematology|November 29, 2019
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialAndrea Kühnl, Clare Peckitt, Bijal Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2019
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaBrad S Kahl, Mehdi Hamadani, John Radford, et al.
Blood|April 9, 2008
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialAnton Hagenbeek, Ole Gadeberg, Peter Johnson, et al.
The Oncologist|February 26, 2014
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study)Marta Bruno Ventre, Andrés J M Ferreri, Mary Gospodarowicz, et al.
Blood|September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphomaPhilippe Armand, Ann Janssens, Giuseppe Gritti, et al.
Pageof 11